Adjunctive Medications for Use in Pediatric Home Cleanout among Children with Chronic Constipation

Jianne De Raya, PharmD Candidate 1; Amy Kruger Howard, PharmD 1; Samra Blanchard, MD 2; Jill A. Morgan, PharmD, BCPS, BCPPS 1

1. University of Maryland School of Pharmacy, Baltimore, MD, USA 2. University of Maryland Medical Center, Baltimore, MD, USA



BACKGROUND

- Functional constipation is a common problem in approximately one in ten children ¹
- Approximately 50% of children with functional constipation will require fecal disimpaction prior to initiation of maintenance treatment ²
- North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) 2014 guidelines for the management of functional constipation recommends the use of polyethylene glycol (PEG) over enemas for fecal disimpaction ³
- Both medications are considered equally efficacious, however PEG is preferred over enemas because of its route of administration ³
- Despite being preferred monotherapy, it is common to see PEG prescribed with additional agents (i.e. senna, mineral oil, magnesium hydroxide, or enema) for disimpaction ³

OBJECTIVES

Primary

- Describe the adjunctive therapies used in combination with PEG for home cleanouts in an outpatient pediatric gastrointestinal (GI) clinic Secondary
- Determine the percentage of patients who received doses in accordance with NASPGHAN guidelines or pediatric reference dosing recommendations

METHODS

Study Design

 Retrospective, convenience sample, multi-site review of pediatric patients who visited the University of Maryland Pediatric GI Clinic with a diagnosis of functional constipation and were prescribed a cleanout from September 2017 through October 2018

Statistical Analysis

- Descriptive statistics to assess patient demographics and medication use and reported means (SD) or medians (IQR) as appropriate
- Appropriateness of therapy was defined as dosing within the reference ranges (see Table 1)

	Inclusion Criteria	Exclusion Criteria
•	Age 13 months to 18 years Diagnosis of functional constipation AND Prescribed at-home disimpaction (cleanout) with PEG	 Missing documented weight on retrospective chart review Diagnosis of Hirschsprung's, diabetes, cystic fibrosis, hypothyroidism, lead poisoning OR
		 Concomitant use of bismuth
		or opiates

Table 1. Recommended Daily Doses for Treatment of Functional Constipation According to NASPHGAN and Lexicomp

Medication	NASPGHAN	Lexicomp
Bisacodyl		
3 to 9 years	5 mg	5 mg
10 to 11 years	5 – 10 mg	5 – 10 mg
≥12 years	5 – 10 mg	5 – 15 mg
Magnesium Citrate		
2 to 5 years	N/A	60 – 90 mL
6 to 11 years	N/A	100 – 150 mL
≥12 years	N/A	150 – 300 mL
Magnesium Hydroxide		
2 to 5 years	400 – 1,200 mg	400 – 1,200 mg
6 to 11 years	1,200 – 2,400 mg	1,200 – 2,400 mg
≥12 years	2,400 – 4,800 mg	2,400 – 4,800 mg
Senna		
2 to 5 years	2.5 – 5 mg	4.3 – 17.2 mg
6 to 11 years	7.5 – 10 mg	8.6 – 34.4 mg
≥12 years	15 – 20 mg	17.2 – 68.8 mg
Enema		
2 to 4 years	2.5 mL/kg *	33 mL
5 to 11 years	2.5 mL/kg *	66 mL
≥12 years	2.5 mL/kg *	133 mL

*max 133 mL

REFERENCES & CONTACT INFORMATION

- Koppen IJN, Vriesman MH, Saps M, Rajindrajith S, Shi X, van Etten-Jamaludin FS, DiLorenzo C, Benninga MA, Tabbers MM. Prevalence of Functional Defecation Disorders in Children: A Systematic Review and Meta-Analysis. The Journal of Pediatrics. 2018;198:121–130.
- Koppen IJN, Lammers LA, Benninga MA, Tabbers MM. Management of Functional Constipation in Children: Therapy in Practice. Paediatr Drugs. 2015;17(5):349-360. doi:10.1007/s40272-015-0142-4
- Tabbers MM, DiLorenzo C, Berger MY, Faure C, Langendam MW, Nurko S, Staiano A, Vandenplas Y, Benninga MA. Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations from ESPGHAN and NASPGHAN. Journal of Pediatric Gastroenterology and Nutrition. 2014;58:258–274. doi:10.1097/MPG.000000000000266

RESULTS

• A total of 54 participants included in the final study analysis, the majority were female and white (see Table 2)

Table 2. Demographic Summary

Participant Domographics	Total (n-E4)
Participant Demographics	Total (n=54)
Median Age (years, IQR)	9 (6.3, 12)
Female (n, %)	28 (51.9)
Median Weight (kg, IQR)	30.1 (23, 39.9)
Race/ethnicity (n, %)	
White	22 (40.7)
Black	14 (25.9)
Other/Non-specific	16 (29.6)
Latino	2 (3.7)
Previous Dx of Chronic Constipation (n, %)	39 (72.2)
Median Age of Onset (years, IQR)	5 (2.6, 8.5)
On Medications Prior to Presentation (n, %)	27 (50)

- Dosing was appropriate in 53% of all adjunctive therapies (100% magnesium hydroxide, 71.88% senna, 52.63% magnesium citrate, 33.33% bisacodyl, 30.76% sodium phosphate enema)
- Doses exceeded either NASPGHAN or Lexicomp recommendations in 100% of inappropriately dosed adjunctive therapy


Table 3. Summary of Medications Prior to Presentation

Medications Prior	n (%)	
Single Med, n=19	PEG 3350	18 (66.7)
	Magnesium hydroxide	1 (3.7)
Dual Med, n=7	PEG 3350 + Senna	2 (7.4)
	PEG 3350 + Mineral Oil	2 (7.4)
	PEG 3350 + Lactulose	1 (3.7)
	PEG 3350 + Magnesium Hydroxide	1 (3.7)
	Lactulose + Enema	1 (3.7)
Triple Med, n=1	Bisacodyl + Magnesium Hydroxide + Senna	1 (3.7)

Table 4. Summary of Medication Regimen for Cleanouts

Medication Regimen		n (%)
Single Med, n=1	PEG 3350	1 (1.9)
Dual Med, n=25	PEG 3350 + Magnesium Citrate	13 (24.1)
	PEG 3350 + Senna	10 (18.5)
	PEG 3350 + Bisacodyl	1 (1.9)
	PEG 3350 + Magnesium Hydroxide	1 (1.9)
Triple Med, n=28	PEG 3350 + Senna + Enema	22 (40.7)
	PEG 3350 + Magnesium Citrate + Enema	4 (7.4)
	PEG 3350 + Magnesium Citrate + Bisacodyl	2 (3.7)

Figure 1. Percentages Dosed Appropriately Based on NASPGHAN and Lexicomp



DISCUSSION

- Only one of the 54 patients were treated with a regimen aligning with NASPGHAN guidelines
- Future studies are necessary to determine if cleanout success is dependent on these additional medications or higher doses and which patients require adjunctive medications.